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Abstract 8 
At early drug discovery, purified protein-based assays are often used to 9 
characterize compound potency. In the context of dose response, it is often 10 
perceived that a time-independent inhibitor is reversible and a time-dependent 11 
inhibitor is irreversible. The legitimacy of this argument is investigated using a 12 
simple kinetics model, where it is revealed by model-based analytical analysis 13 
and numerical studies that dose response of an irreversible inhibitor may appear 14 
time-independent under certain parametric conditions. Hence, the observation of 15 
time-independence cannot be used as sole evidence for identification of inhibitor 16 
reversibility. It has also been discussed how the synthesis and degradation of a 17 
target receptor affect drug inhibition in an in vitro cell-based assay setting. These 18 
processes may also influence dose response of an irreversible inhibitor in such a 19 
way that it appears time-independent under certain conditions. Furthermore, 20 
model-based steady-state analysis reveals the complexity nature of the drug-21 
receptor process. 22 
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1 Introduction 29 
Drug discovery and development typically involve protein-based studies (e.g. target 30 
engagement; typical time scale: microseconds to minutes), in vitro cell-based studies (e.g. 31 
biomarker pharmacodynamics (PD), therapeutic efficacy; typical time scale: minutes to days), 32 
in vivo animal-based studies (e.g. pharmacokinetics (PK), biomarker PD, therapeutic efficacy, 33 
safety evaluation; typical time scale: hours to days) and clinical trials (e.g. PK, PD, safety, 34 
efficacy; typical time scale: days to months). These studies are often organized in this 35 
particular temporal order, in the hope that the results of a previous step (e.g. protein-based 36 
assay) will help inform the design and interpretation of the subsequent experiment (e.g. in 37 
vitro cell assay). 38 
A new paradigm that helps enable robust translation of each type of study arises in recent 39 
years [1], in which mathematical models and model-based systems analysis have played 40 
increasingly important roles. Model development of drug processes using experimental data 41 
has been largely improved through various efforts including sensitivity analysis, parameter 42 
identifiability analysis, model approximation and simplification, model validation and 43 
comparison, etc. [2-5].  44 
Known as Quantitative & Systems Pharmacology (QSP), it employs multi-scale 45 
modelling approaches to integrate data generated from different studies in a drug discovery 46 
and development programme, which span different temporal and dimensional scales [6-8]. 47 
These computational models are able to reconcile different experimental conditions (e.g. in 48 
vitro cell assays and in vivo animal models [9]), with an ultimate aim of bridging preclinical 49 
models to an appropriate clinical setting, and generating statistically robust predictions that 50 
are validated by preclinical and clinical data [10].  51 
Multi-scale modelling has been successfully deployed in drug development programmes, 52 
so that in vitro cell-based studies are consistently integrated with in vivo animal-based studies. 53 
However, the application of QSP approaches in early drug discovery (i.e. integration of 54 
results from protein-based studies and in vitro cell-based studies) has been relatively limited 55 
[11]. QSP models are urgently needed to better understand target engagement in cell-free 56 
environment and in cells, so as to help design of subsequent in vitro and in vivo studies [1].  57 
It is often important to establish dose±response relationship specific for an inhibitor and a 58 
cell type under investigation, which describes the change in effect on a cell caused by 59 
differing levels of exposure (or doses) to an inhibitor after a certain exposure time.  60 
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To help translate in vitro results into in vivo knowledge, models of Target Mediated Drug 61 
Disposition (TMDD) have been developed to analyse receptor PK/PD relationships [2-5; 7; 8; 62 
12-15]. In addition to drug binding and receptor turnover, these models also consider the 63 
elimination of all species, to mimic in vivo conditions. They can be served as a useful 64 
theoretical framework. Model-based analysis revealed that the necessary and sufficient 65 
condition for receptor rebound in a single dose animal experiment is that elimination rate of 66 
the drug-receptor product being slower than the elimination rates of the drug and of the 67 
receptor [12]. Under the assumption of a constant target pool, the characteristic features of 68 
TMDD dynamics were studied through a mathematical model analysis [13]. A time-scale 69 
analysis was performed to provide accurate approximations of the temporal evolution under 70 
the assumption of high drug binding affinity [14].  71 
Although TMDD models have been used increasingly to facilitate PK/PD studies, cellular 72 
kinetics may sometimes not be fully appreciated in design of protein-based assays. For 73 
instance, the potency of a chemical entity to inhibit an enzyme is often characterized by IC50, 74 
the chemical concentration that generates half of maximal inhibition. For an irreversible 75 
inhibitor that covalently modifies a purified target enzyme in a cell-free assay, the chemical 76 
reaction tends to be more complete given a longer drug incubation period. Consequently, IC50 77 
usually exhibits incubation time-dependent shift, making the inhibitor appear more potent at 78 
long incubation periods [16-18]. In contrast, a target protein in a living cell undergoes 79 
turnover (i.e. synthesis and degradation) that are often regulated via transcriptional regulation, 80 
translational control [19] and cell signalling etc. These processes typically happen within 81 
minutes to hours [20], and they may influence cellular response to drug inhibition. In other 82 
words, shooting a moving target in a cell might be different from shooting an immobile target 83 
in a protein-based assay.  84 
The aim of this study is to investigate how drug parameters and cell parameters influence 85 
cellular response to drug treatment at constant drug concentration. We are interested in 86 
understanding whether an irreversible inhibitor necessarily has an incubation time-dependent 87 
IC50 in a protein-based study. In addition, we hope to examine how cell parameters including 88 
target synthesis and degradation rates affect dose response.  89 
The remaining of the paper is organized as follows. A linear model of receptor turnover 90 
and irreversible inhibition is proposed and discussed in Section 2. Investigation of fast drug 91 
process relative to receptor turnover is discussed in Section 3, where both numerical 92 
simulation and ensuing analysis of the eigenvalues are employed. Discussions on slow drug 93 
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process relative to receptor turnover are presented in Section 4. In Section 5, an application of 94 
this model is attempted using aberrant activity in Epidermal Growth Factor Receptor (EGFR) 95 
signaling data. Conclusions are given in Section 6. 96 
2 A model of receptor turnover and drug inhibition 97 
A simple model is proposed to recapitulate the process of receptor turnover, i.e. receptor 98 
synthesis and degradation, together with drug inhibition as shown schematically in Fig. 1. 99 
R ± receptor
C - complex
pk
dk
onk
offk
C
ik
R
Receptor 
turnover
Drug 
inhibition
 
100 
Fig. 1 Schematic description of receptor turnover and irreversible inhibition 101 
In the receptor turnover process, receptor R is synthesized at a constant rate pk , and degrades 102 
following a first-order kinetics with a rate constant dk . For the sake of simplicity, feedback 103 
mechanisms and subcellular localisation that regulate protein synthesis and stability are not 104 
considered in this model. In the drug inhibition process, a drug molecule first binds R 105 
reversibly to comprise an intermediate complex C with association and dissociation rates onk  106 
and offk , respectively. Note that onk  is an apparent rate that depends on drug concentration. 107 
The complex C then forms a covalent bound irreversibly at the second step, in a first-order 108 
reaction with a rate constant ik . These two processes can be described respectively as follows. 109 
Receptor turnover: Ro op dk k                                                                 (1) 110 
Drug inhibition: R Coon i
off
k k
k                                                              (2) 
111 
Based on mass-balance principles, the corresponding ordinary differential equations (ODEs) 112 
for concentrations of R and C, denoted as R and C, respectively, are written as 113 
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d
d d on p off
R k k R k k C
t
    
                                             (3) 114 
 dd on off iC k R k k Ct                                                           (4) 115 
with the following units: nM for R, C; nMÂmin-1 for pk ; and min-1 for dk , onk , offk  and ik . 116 
Here pk  and dk  are cell parameters associated to receptor turnover; onk , offk  and ik  are drug 117 
parameters for covalent inhibition process. 118 
In the absence of drug, the receptor has a steady state at 0 p dR k k  nM. Scaling R and C 119 
with 0R  in (3) and (4), the two concentration variables become dimensionless terms 120 
0 d pr R R Rk k   and 0 d pc C R C k k  , respectively, and the ODE model can then be 121 
written as 122 
 d
d d on d off
r k k r k k c
t
    
                                              (5) 123 
 dd on off ic k r k k ct                                                             (6) 124 
In this dimension-free representation, the initial conditions are set to be  0 0 1r r   and 125 
 0 0 0c c  . We further use offk  to scale the time term by offk tW  , and also to scale 126 
reaction rates with on on offk kN  , i i offk kN  , and d d offk kN  . This brings the following 127 
two ODEs for dimensionless r and c, respectively: 128 
 d
d on d d
r
r cN N NW                                                       (7) 129 
 d 1
d on i
c
r cN NW                                                               (8) 130 
Denoting > @Tr c X , this ODE model can be written in a matrix format 131 
 
 
0
d
1d
1d 0
d
with (0)
on d d
on i
r
r r
c c c
N N NW
N N
W
ª º« »  ª ºª º ª º ª º   « » « »« » « » « » ¬ ¼ ¬ ¼ ¬ ¼¬ ¼« »« »¬ ¼
   
X
AX f X X
                            (9) 132 
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where    
1
1
on d
on i
N N
N N
 ª º « » ¬ ¼
A  is the state matrix for this linear-time-invariant (LTI) 133 
system; > @T0dN f  is the nonhomogeneous part; > @T0 1 0 X  is the vector of initial states 134 
for X.  135 
At the steady state when d d 0r W   and d d 0c W  , the steady-state values for r and c are 136 
derived from (9) to give 137 
 
 
1
1
i d
ss
i d on i
r
N N
N N N N
                                                         (10) 138 
 1 on dss i d on ic
N N
N N N N                                                        (11) 139 
Here ssr  and ssc  are used to denote steady-state values or equilibrium points for r and c, 140 
respectively, when time approaches infinity.  141 
Note after the above re-scaling, all terms in (9) are dimensionless including concentration 142 
variables r and c; time W ; and parameters onN , iN , and dN . The µGLVDSSHDUHG¶ receptor 143 
synthesis rate pk  is included in dN  through scaling of  0d d off p offk k k k RN   . Clearly this 144 
choice of non-dimensionalization requires that 0offk z  and 0pk z . All variables and 145 
parameters in (9) are associated with physical quantities and therefore must be nonnegative. 146 
With this dimensionless model, the analysis of system behaviour under different parametric 147 
regimes can be conveniently discussed in a unified scheme. 148 
3 Fast drug process relative to receptor turnover 149 
The parametric regimes have been divided into that of fast drug process and slow drug 150 
process. In this section, the process of fast drug binding and dissociation is firstly discussed. 151 
3.1 Fast drug binding and dissociation relative to receptor turnover 152 
This parametric regime is defined by off dk k  and on dk k . In this case, the receptor 153 
turnover rate dk  is much smaller than the drug binding and dissociation rates onk  and offk .  154 
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(a) When off dk k , i.e., 1dN , the period of target coverage (characterized by 1 offk ) 155 
is much shorter than that of receptor degradation (characterized by 1 dk ), which can 156 
be due to: i) short target coverage; ii) slow receptor degradation; and iii) combination 157 
of i) and ii). 158 
(b) When on dk k , i.e., on dN N , a receptor binds a drug molecule at a rate much faster 159 
than its degradation.  160 
Under these two conditions, the term of dN  can be ignored, and model (9) is approximated by 161 
 
1
1
N
N N
ª ºª º ª º « »« » « » ¬ ¼ ¬ ¼¬ ¼
on
on i
r r
c c
                                                            (12) 162 
Model (12) is actually an ODE model for the cell-free assay with only the drug process in (2)163 
considered.  164 
When 0iN z , by taking d d 0r W   and d d 0c W  , the steady-state of dynamic system 165 
(12) is deduced to be  166 
0ss ssr c                                                                                     (13) 167 
How small does dk  have to be in comparison to offk  and onk  so as to ensure the validity 168 
of this approximation? This is examined by the following numerical simulation. Firstly, the 169 
full model in (9) is simulated with 0.001iN   ( off ik k ) at three different levels of dN : 170 
410dN   (Fig. 2 (a)); 610dN   (Fig. 2 (b)); and 810dN   (Fig. 2 (c)). Then the full model is 171 
simulated by taking 0dN  , which is equivalent to the reduced model in (12), using identical 172 
value for iN , as shown in Fig. 2 (d). The range of onN  is set to be [1e-5, 1e5] in all 173 
simulations. Four incubation time periods are chosen which are separated with an order of 3 174 
in time scale between each two, i.e., 10-3, 1, 103 and 106. Comparing simulation results across 175 
the four panels in the semi-log Fig. 2, it can be observed that there is a clear difference in 176 
dose response in both Fig. 2 (a) and Fig. 2 (b) when compared with the simplified model 177 
results in Fig. 2 (d), but the dose response in Fig. 2 (c) is almost the same as that in Fig. 2 (d). 178 
This shows that, when 810dN d , model (12) provides a close approximation for dose 179 
responses corresponding to incubation time up to 106.  180 
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In all simulation and illustrative results in this paperWKHWLPHWHUPVDUHUHSUHVHQWHGLQĲ181 
(time t scaled by offk ), and the x-axis for onN  is in log10 scale in dose-response curves. 182 
 183 
       (a) Full model at 410N  d                                 (b) Full model at 610dN   184 
 185 
       (c) Full model at 810
d
N  
                            (d) Simplified model (12) 186 
Fig. 2 Dose response curves predicted for four different incubation times, when 0.001iN  . 187 
Incubation times shown in the figure legend: black dotted line for 10-3; red line with circles 188 
for 100; blue dash-dot line for 103; green solid line for 106. (a) Full model (9) simulated at 189 
410dN  ; (b) Full model simulated at 610dN  ; (c) Full model simulated at 810dN  ; (d) 190 
Approximate model in (12). 191 
The approximate model in (12) represents a homogeneous LTI system with 192 
 
1
1
on
on i
N
N N
ª º « » ¬ ¼
A . We can use the eigenvalue method to analyse its dynamic 193 
characteristics. Denoting the trace and determinant of matrix A as 194 
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trace( ) 1 N N    A on iT , det( ) N N'   A on i , the eigenvalues of A are calculated by 195 
 21,2 4 2T TO   ' . 196 
For the first eigenvalue 197 
   21 1 11 1 4 ,2 2on i on i on iO N N N N N N                                      (14) 198 
its associated eigenvector is  199 
> @  
T
2
T
1 11 21
1 1 4
1 .
2
i on on i on i
on
v v
N N N N N NQ N
ª º     « »  « »¬ ¼
                              (15) 200 
For the second eigenvalue 201 
   22 1 11 1 4 ,2 2on i on i on iO N N N N N N                                      (16) 202 
its associated eigenvector is  203 
> @  
T
2
T
2 12 22
1 1 4
1 .
2
i on on i on i
on
v v
N N N N N NQ N
ª º     « »  « »¬ ¼
                             (17) 204 
With initial conditions ݎ଴ ൌ  ? and ܿ଴ ൌ  ?, a general analytical solution for (12) can be 205 
succinctly written as  206 
1 2
1 2
11 12
11 12
( ) 1( ) ( )
r e e
c e e
OW O W
O W O W
W Q QW W Q Q
ª ºª º  « »« »  ¬ ¼ ¬ ¼
M
                                                (18) 207 
where all terms regarding eigenvalues and entries in eigenvectors are provided in (14) - (17). 208 
The log10 transformed ratio of the two eigenvalues for different pairs of ( onN , iN ) is 209 
plotted in a heat map as shown in Fig. 3. From this diagram it is evident that when the two 210 
parameters have similar values and are both above 1, the two eigenvalues 1O  and 2O  are close 211 
to each other (the red area in Fig. 3). However, if only one parameter is much larger than 1 or 212 
both parameters are much smaller than 1, then the two eigenvalues are widely apart from 213 
each other, i.e. 2 1/ 1O O  (the blue area in Fig. 3), and the time response of the system is 214 
mainly determined by 1O  in a shorter period. 215 
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 216 
Fig. 3 10 2 1log ( / )O O  plotted as a function of 10log ( )onN  and 10log ( )iN . Values between -10 217 
and 0 are colour-coded. 218 
I IIIII
 219 
Fig. 4 Time responses of r and c under 1onN  , 0.001iN   and 0dN  .  220 
For example, when 1onN  , 0.001iN  , from (14) to (17), the eigenvalues and 221 
eigenvectors can be calculated as: 1 2.005O   , 42 5 10O   u , > @T1 0.7069 0.7069Q    and 222 
> @T2 0.7073 0.7069Q    . The short-term time response is driven by 1O  (see region I in Fig. 223 
4), and the long-term time response is driven by 2O  (see region III in Fig. 4). Interestingly, 224 
between these two regions, both r and c have relatively small variations (see region II in Fig. 225 
4). Hence, corresponding dose responses simulated for observation times in this shadowed 226 
region would appear to be similar using experimental data. This time-independent 227 
observation may suggest a reversible inhibition, which is not true from the above analysis. 228 
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3.2 Fast drug binding/dissociation and fast covalent modification  229 
The parametric regime for this scenario is classified by: on dN N , off dN N , and 230 
i onN N| , therefore i dN N . In this case, both reversible binding/dissociation and irreversible 231 
modification are much faster than receptor turnover. The system can also be modelled by (12). 232 
It can be seen from the heat map in Fig. 3 that the two eigenvalues are close to each other in 233 
this region, which means the two inherent time scales are not far away from each other. For 234 
the simulations demonstrated in Fig. 5, the two eigenvalues are 1 2.618O    and 2 0.382O   , 235 
calculated from (14) and (16), respectively. In this case, the dose response curves measured at 236 
different incubation times are predicted to be clearly separated from each other (Fig. 5 (a)).  237 
The concentrations of R and C reach steady states with both values at 0 (Fig. 5 (b)), which 238 
is consistent with the steady-state analysis conclusion given in (13). Similar to the simulation 239 
results shown in Fig. 4, Fig. 5 (b) also demonstrates that the receptor concentration decreases 240 
monotonically to its steady state, but the complex concentration goes through a rapid increase 241 
initially and then decreases in a slower time scale to its steady state. 242 
  243 
           (a) Dose response curves                                 (b) Time responses under 1onN   244 
Fig. 5 Dose response curves and time responses of r and c under 0,dN   1on iN N  .  245 
3.3 Fast drug binding/dissociation and slow covalent modification 246 
Under the condition of fast drug process over receptor turnover ( off dk k  and on dk k ), 247 
we further consider the regime of off ik k , i.e., 1.iN  This means the drug dissociation is 248 
much faster than the covalent modification. It corresponds to the region in lower part of the 249 
heat map in Fig. 3. This condition is satisfied if i) an irreversible inhibitor has to overcome a 250 
12 
 
relatively large energy barrier to covalently modify the receptor; ii) drug dissociation is rapid; 251 
iii) a combination of both. Within the parametric region of on dN N , 1dN  and 1,iN  252 
model (12) can be further reduced to 253 
1
1
N
N
ª ºª º ª º « »« » « »¬ ¼ ¬ ¼¬ ¼
on
on
r r
c c
                                                                    (19) 254 
Model (19) is a description for protein-based assay when reversible inhibitor is applied 255 
while the covalent modification is negligible. In order to determine how small iN  should be 256 
so that the simplified model in (19) can be applied, simulations are conducted using the full 257 
model under 810 ,dN   and reduce iN  gradually to search for the threshold level that will 258 
produce a response close to the simplified model response. Fig. 6 shows that when iN  is 259 
reduced to 71 10 ,u  the full-model response is very close to that of the simplified model (19). 260 
This suggests that when 710 ,iN d  the simplified model in (19) can be used to approximate 261 
model (12) with a good accuracy. 262 
 263 
 (a) Full model at 8 71 10 , 1 10d iN N  u  u                   (b) Approximate model (19) 264 
Fig. 6 Dose response curves predicted for different incubation times in W : black dotted line 265 
for 10-3; red line with circles for 100; blue dash-dot line for 103; green solid line for 106. (a) 266 
Full model (9) simulated at 8 71 10 , 1 10d iN N  u  u ; (b) Approximate model in (19).  267 
In this case, d d
d d
r c
W W  ,  trace( ) 1 onT N   A , det( ) 0'   A , 1 ( 1)onTO N     and 268 
2 0O  . Under the given initial conditions, the time responses of the two dimensionless 269 
concentration terms can be solved explicitly to yield 270 
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1
1
1( ) 1
1
( ) 1
1
on
on
on
on
on
on
r e
c e
N W
N W
W NN
NW N
 
 
 
 
                                                                    (20) 271 
The time scale of this dynamic system is determined by 1O  or by onN . The larger is onN , the 272 
faster response the system has, and vice versa. The time responses of r  and c  under different 273 
levels of onN  are illustrated in Fig. 7. 274 
With model (19), the steady state is not determined by (13) since iN  is taken to be zero. In 275 
fact, the equilibrium points for system (19) can be derived from (20) to give  276 
  
  
1
1
1 1lim 1
1 1
lim 1
1 1
on
on
ss on
on on
on on
ss
on on
r e
c e
N W
W
N W
W
NN N
N N
N N
 
of
 
of
    
    
                                            (21) 277 
It can be concluded that 1ss ssr c   at the steady state. The larger is onN , the smaller is ssr  278 
and the larger is ssc . This can be clearly seen in the dynamic simulation results shown in Fig. 279 
7. 280 
 281 
      (a) Time response r                                              (b) Time response c   282 
Fig. 7 Time responses of r and c with approximate model (19) under different levels of onN . 283 
For incubation time  1 1 ,W Nm on  r is close to its steady state (see simulation for each 284 
Non  in Fig. 7). Hence, dose response measurements taken beyond this point would appear 285 
time-invariant.  286 
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In summary, our analysis of fast drug process suggests for dose response to appear time-287 
invariant, the following two requirements need to be satisfied. Firstly, the apparent first-order 288 
rate Non  and the first-order covalent bond formation rate N i  need to be largely different so 289 
that the two time scales characterized by 11 O  and 21 O  are well separated from each other. 290 
Secondly, observation time has to be between the two time scales, which corresponds to 291 
region II in Fig. 4. It can also be observed from dynamic study that the receptor concentration 292 
always decreases monotonically to a steady-state level of zero for the fast drug process, while 293 
the concentration of complex C increases rapidly first and then decreases gradually to zero 294 
except for the case when covalent modification to complex C is negligible, i.e. 0iN  . 295 
4 Slow drug process relative to receptor turnover 296 
In the parametric regime where off dk k|  or off dk k , i.e. 1dN |  or 1dN , target 297 
coverage duration is comparable to or longer than the receptor life time. This can happen due 298 
to: i) long period of target coverage; ii) fast receptor degradation; and iii) combination of both. 299 
This might be biologically relevant when receptor homeostasis is tightly regulated at the 300 
turnover level. The full model in (9) is used in this regime. 301 
Again the eigenvalue method can be used to analyze the system dynamics. The 302 
homogeneous part of (9) is  X AX . The trace of A is  trace( ) 1 on d iT N N N     A , 303 
the determinant of A is det( ) d on i d iN N N N N'    A . The two eigenvalues are 304 
 21,2 1 42 T TO   ' . 305 
For  21 1 42 T TO    ' , the associated eigenvector is  306 
> @    
T
2
T
1 11 21
1 1 4
1 .
2
i on d i on d on
on
v v
N N N N N N NQ N
ª º       « »  « »¬ ¼
 307 
For  22 1 42 T TO    ' , the associated eigenvector is  308 
> @    
T
2
T
2 12 22
1 1 4
1 .
2
i on d i on d on
on
v v
N N N N N N NQ N
ª º       « »  « »¬ ¼
 309 
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Under the initial condition of > @T0 1 0 X , the general solution to the homogeneous part 310 
can be written as ( )WM  in (18). Taking the non-homogeneous part > @T0dN f  into account, 311 
the general solution to (9) is written as follows 312 
> @T 1 10 0( ) ( ) ( ) (0) ( ) ( ) ( )dr c t t tWW W W W   ³M M X M M f                                  (22) 313 
The steady-state values of r and c can be obtained through numerical integration with (22), or 314 
calculated explicitly by (10) and (11). 315 
Similar to the heat map in Fig. 3, we first plot 10 2 1log ( / )O O  as a function of onN  and iN  316 
in log10 scales (Fig. 8). Taking off dk k , i.e. 1dN   (Fig. 8 (a)), separation of time scales 317 
happens if either on offk k  and i offk k  (blue region in Fig. 8 (a)), or on offk k  and 318 
i offk k  (light green region in Fig. 8 (a)), with the former leads to more pronounced effects. 319 
In contrast, in the case of 0.001off dk k , i.e. 1000dN   (Fig. 8 (b)), separation of time scales 320 
takes place if i offk k  (bottom part in Fig. 8 (b)), and the condition of on offk k  makes the 321 
separation more pronounced.  322 
 323 
(a) off dk k  324 
16 
 
 325 
 (b) 0.001off dk k  326 
Fig. 8 10 2 1log ( / )O O  plotted as a function of 10log ( )onN  and 10log ( )iN . Values between -10 327 
and 0 are colour-coded. (a) off dk k ; (b) 0.001 off dk k .  328 
The following can be verified in this parametric regime:  11 2 1 0dv O N O   , 329 
12 1 2( ) 0dv O N O ! . Considering the analytic solution, it is likely for r to decrease first with a 330 
time scale determined by 1O  and then recover with a time scale determined by 2O  in the 331 
longer term, if 1O  and 2O  are sufficiently apart. 332 
An example is discussed to illustrate these ideas by taking off dk k  and i dk k . This 333 
means the receptor degradation is as fast as target coverage and the drug overcomes a large 334 
energy barrier to covalently modify the receptor.  335 
Suppose off dk k  and 0.001i dk k . Under this condition, receptor initially decreases as a 336 
result of drug inhibition, and then recovers towards steady states (see Fig. 9 (c) and Fig. 9 (d)). 337 
In the context of dose response curves, this means measurement taken before recovery in r 338 
would make the drug appear more potent than the actual steady-state response. For 1onN  , r 339 
is predicted to be smaller for 1W   than for 10,100,1000W   (Fig. 9 (a)). In addition, this 340 
trend is consistent throughout onN  values to a larger range (Fig. 9 (b)). Hence, the dose 341 
response simulated for 1W  (black dotted curve) appears to be more potent than any other 342 
curves in Fig. 9 (a)-(b).  343 
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  344 
                      (a) 3[1,10 ]W                                                          (b) 6[1,10 ]W   345 
 346 
                 (c) 1on dN N                                                     (d) 10, 1on dN N   347 
Fig. 9 Dose response curves, time response of r and c under 0.001iN  . 348 
According to the heat map in Fig. 8 (a), higher onN  leads to smaller 2O  (the blue region in 349 
Fig. 8 (a)), which makes recovery time in r being longer. To examine this observation, time 350 
responses of r and c are simulated for 1onN   and 10onN  , respectively, as shown in Fig. 9 351 
(c) and (d). It can be seen that time response simulation at 10onN   predicts an elongated 352 
recovery period in r (Fig. 9 (d)) compared with that in 1onN   (Fig. 9 (c)). This observation is 353 
consistent with the separation of different dose response curves in Fig. 9 (a).  354 
In slow drug process, the increase of complex concentration is monotonic over time, while 355 
the receptor concentration first decreases in a short time and then increase towards a constant 356 
level in a longer time. The numerical solutions for r and c at steady states shown in Fig. 9 (c) 357 
and (d) are validated by the model-based analytical results in (10) and (11). 358 
 359 
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5 Applications 360 
Aberrant activity in Epidermal Growth Factor Receptor (EGFR) signaling has profound 361 
implications in different types of tumour. Recently, off onk k  and ik  are reliably quantified 362 
from cell-free assays for different irreversible EGFR mutant (EGFRm) inhibitors [20]. 363 
However, this study was not able to determine the actual values of > @*on on offafatinibk kN   364 
and offk . Instead, 
*
onk , that is > @drugonk  in our context, was assumed to be close to diffusion 365 
limit at 100µM-1s-1 in order to calculate values for offk . The reported values are tabulated 366 
below: 367 
compound koff, s-1 ki, s-1 Ki(nM) 
CI-1033 0.19±0.04 0.011±0.0002 1.9±0.4 
dacomitinib 1.1±0.1 0.0018±0.0001 10.7±0.9 
afatinib 0.3±0.1 0.0024±0.0003 2.8±0.6 
neratinib 0.2±0.1 0.0011±0.0002 2.4±0.5 
CL-387785 18±4 0.002±0.0003 180±40 
WZ-4002 23±5 0.0049±0.0015 230±50 
 
Table 1. Parameter values inferred from reaction progress curves measured for H1975 cells 368 
carrying L858R and T790M mutations in EGFR, using an ODE model. This table is 369 
reproduced from the supplementary information in [20]. The plus-or-minus values are 370 
standard deviations from averaging three replicated, entirely independent experiments. 371 
i on offK k k .  372 
We simulated the cell-free assay of afatinib by using the model in (9) by taking 0.N  d  This 373 
predicts the IC50 for onN  at 30-minutes incubation has a mean value of  ?Ǥ ? ? (i.e. assuming 374 
3 12.4 10 sik
  u , 10.3soffk  ) (see Fig. 10 (a)). Since * ][on on offafatinibk kN   DIDWLQLE¶V375 
IC50 at 30-minutes incubation is predicted to be 0.4nM. Considering different combinations 376 
of ik  and offk  values as UHSRUWHG LQ 7DEOH  DIDWLQLE¶V ,&50 at 30-minute incubation is 377 
predicted to be within the range of [0.27,0.6] nM.  378 
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It is reported that the internalisation rate of EGFR receptor is approximately 0.2min-1 in 379 
breast cancer cells [21]. Hence, 21.1 10d d offk kN   u . Considering 38.0 10iN  u , this is 380 
similar to the fast drug process parametric regime discussed in Section 3.3. Model simulation 381 
in Fig. 6 suggests dose response curves taken at 1W   and 100W   should be close. 382 
Using model (12) to mimic in vitro cell assay conditions by taking 21.1 10 ,dN  u  simulated 383 
dose response curves at different incubation durations shift further to right (Fig. 10 (b)) 384 
compared with that of 0N  d  (Fig. 10 (a)). In Fig. 10 (b), with IC50 for onN  at 1-hour 385 
incubation at approximately 1.4, a 10-fold increase from the predicted protein-based assay 386 
(i.e. 0.13) is observed. Consistent with these simulation results, approximately 10-fold 387 
difference was reported for cell-based assay and protein-based assay for afatinib [21] 388 
It can be seen from the above discussions that the simple model in (9) can be used 389 
conveniently to generate insights into the connections and differences between protein-based 390 
assay and cell-based assay. 391 
 392 
(a) 0dN  , 38.0 10iN  u . This mimics             (b) 21.1 10dN  u , 38.0 10iN  u . This  393 
              the cell-free assay condition.                               mimics the in vitro cell assay. 394 
Fig. 10 Simulated dose response curves for afatinib. 395 
6. Conclusions and discussions 396 
At lead generation and optimization, it is important to understand the Mechanism Of 397 
Action (MOA) of a chemical compound, as well as the Structure-Activity Relationship 398 
(SAR), in the hope that ultimately a compound with sufficient therapeutic efficacy is taken 399 
further for preclinical development. Reversibility of a compound is a crucial aspect of MOA 400 
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characterisation. This often remains unknown for compounds coming out of empirical 401 
screening methods. Towards this goal, assays have been established to study inhibition 402 
reversibility [22]. It is generally accepted that response to irreversible inhibitors are time-403 
dependent. Hence, it is often taken for granted that time-independence indicates inhibition 404 
reversibility. However, our model-based analysis refutes this claim.  405 
We demonstrated iff inhibitor binding and dissociation processes are much quicker than 406 
receptor turnover, this system can be approximated by one concerning inhibition only, which 407 
is equivalent to the protein-based assay. Based on the numerical simulation using a simple 408 
model, it is observed that for protein-based assays, under certain parameter conditions, the 409 
dose response curves can be very similar to each other (compare the middle curves in Fig. 2 410 
(d)), given 1000-fold variation in incubation time. This indicates dose responses might appear 411 
time-invariant for a particular parameter setting. In practice, these data might not be 412 
statistically different and can be erroneously taken as evidence of reversible inhibitor.  413 
We subsequently analyzed the impact of cell parameters on dose response, including target 414 
synthesis and degradation, using the proposed model. Our ensuing analysis of the eigenvalues 415 
provides a more general understanding. For dose response to appear time-invariant, the 416 
apparent first-order association rate Non  and the first-order covalent bond formation rate N i  417 
need to be well separated so that the system has two very different time scales. In particular, 418 
when a slowly-dissociating irreversible drug is applied to a receptor under fast turnover, dose 419 
response may be highly similar to each other under a variety of incubation periods. Hence, it 420 
is inappropriate to conclude an inhibitor being reversible given time-independent dose 421 
response, either based on protein-based assay or cell-based assay. 422 
The main purpose of this analysis is to demonstrate the relationship between dose response 423 
and parameter values in drug and cell processes. For the sake of simplicity, we only 424 
considered a linear model in which each reaction follows first-order kinetics. In addition, we 425 
did not consider biological regulation over synthesis, degradation and sub-cellular 426 
localisation of a receptor [20]. Results obtained in this paper are specific to the form of this 427 
linear model. In reality, receptors are often regulated under different levels via feedback 428 
mechanisms. This often necessitates mechanistic modelling of a biological pathway to aid in 429 
interpretation of in vitro cell assays.  430 
It is evident from both numerical simulation and analytical study that the proposed model 431 
is globally asymptotically stable. For the fast drug process considering complex elimination, 432 
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the reduced model (12) is proposed. The receptor concentration decreases monotonically to 433 
its steady-state level of zero, while the complex concentration initially increases rapidly and 434 
then decreases gradually to zero when the complex elimination is considered (see (13) for 435 
steady-state calculation). When the complex elimination is negligible, the reduced model (19) 436 
is used. The system will have non-zero steady states for both r and c following a conservation 437 
law of 1ss ssr c   (see (21) for the explicit solution). For the slow drug process including 438 
both reactions (1) and (2), the full model (9) is used to describe the dynamic system, and the 439 
steady-states are explicitly represented by (10) and (11) for r and c, respectively. In this case, 440 
the complex concentration increases monotonically over the whole process, but the receptor 441 
concentration first decreases rapidly and then increases gradually on a slower time scale back 442 
towards its steady state. The similar rebound behaviour in receptor was also observed and 443 
discussed in other TMDD model-based studies [12; 14; 15]. 444 
For a drug discovery and development programme, the in vitro model should be used to 445 
identify parameter values from in vitro data. These parameters can be used subsequently to 446 
help identify the remaining parameter values in the in vivo model. This step-wise fitting may 447 
reduce uncertainty in parameter estimation. In this context, the in vitro model described in 448 
this paper improves the utility of TMDD models.  449 
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